| Weight reducing and metabolic effects of topiramate in patients with migraine--an observational study. | |
| | |
MedLine Citation:
|
PMID: 20200812 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Topiramate is an anticonvulsant agent effective in the prophylaxis of migraine, which also induces weight reduction by an unknown mechanism. We investigated the effect of topiramate on metabolic and endocrine parameters in patients with migraine independently of any intention to lose body weight. Six patients (26-61 years old, body mass indices [BMI] 20.9-32.1 kg/m(2)) with migraine were treated with an average dose of 100 mg topiramate/day over a period of 20 weeks. The following parameters were measured every 4-8 weeks: BMI, body fat proportion, waist and hip circumference, HOMA insulin resistance, fasting serum-/plasma concentrations of adiponectin, leptin, ghrelin, vascular endothelial growth factor (VEGF), cortisol, interleukin-6 and tumor necrosis factor (TNF)-alpha. Profound metabolic changes were observed for the whole treatment period. Compared with the baseline value, 20 weeks of treatment reduced the BMI by 7.2+/-1.4%, body fat proportion by 11.6+/-3.6%, waist circumference by 4.2+/-1.2%, leptin by 39.2+/-6.5% and HOMA insulin resistance by 37.3+/-5%, while adiponectin was increased by 69.9+/-17.3% (P<0.05, respectively). VEGF concentrations increased during the week 2-4 by 177.4+/-39.4% (P<0.05) followed by a continuous decrease. There were trends for a reduction in ghrelin concentration, whereas cortisol, interleukin-6 and TNF-alpha values were unchanged. In summary, in this small sample of migraine patients topiramate treatment was associated with increased insulin sensitivity, increased adiponectin concentration and a reduction of body fat in all treated patients. The role of increased VEGF concentrations prior to these metabolic changes is not clear and might, hypothetically, involve a centrally mediated effect of topiramate on body weight regulation. |
| | |
Authors:
|
M Schütt; J Brinkhoff; M Drenckhan; H Lehnert; C Sommer |
Publication Detail:
|
Type: Journal Article Date: 2010-03-03 |
Journal Detail:
|
Title: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Volume: 118 ISSN: 1439-3646 ISO Abbreviation: Exp. Clin. Endocrinol. Diabetes Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-09 Completed Date: 2010-10-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9505926 Medline TA: Exp Clin Endocrinol Diabetes Country: Germany |
Other Details:
|
Languages: eng Pagination: 449-52 Citation Subset: IM |
Copyright Information:
|
J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart, New York. |
Affiliation:
|
Department of Internal Medicine I, University of Lübeck, Lübeck, Germany. morten.schuett@uk-sh.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adiponectin
/
blood Adipose Tissue / drug effects Adult Anti-Obesity Agents / administration & dosage* Anticonvulsants / administration & dosage* Body Mass Index Cytokines / blood Female Fructose / administration & dosage, analogs & derivatives* Hip Humans Insulin Resistance Leptin / blood Male Middle Aged Migraine Disorders / drug therapy* Prospective Studies Vascular Endothelial Growth Factors / blood Waist Circumference / drug effects Weight Loss / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Adiponectin; 0/Anti-Obesity Agents; 0/Anticonvulsants; 0/Cytokines; 0/Leptin; 0/Vascular Endothelial Growth Factors; 30237-26-4/Fructose; 97240-79-4/topiramate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of antidiabetic therapies to glycemic control and to body weight in type 2 diabetes: a G...
Next Document: Associations of estrogen receptor alpha and Beta gene polymorphisms with sex steroid levels and body...